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Abstract
Background: Pregabalin may reduce postoperative pain and opioid use. Higher doses may be more effective, but may cause
sedation and confusion. This prospective, randomized, blinded, placebo-controlled study tested the hypothesis that pregabalin
reduces pain at 2 weeks after total knee arthroplasty, but increases drowsiness and confusion.
Methods: Patients (30 per group) received capsules containing pregabalin (0, 50, 100, or 150 mg); two capsules before surgery, one
capsule twice a day until postoperative day (POD) 14, one on POD15, and one on POD16. Multimodal analgesia included femoral
nerve block, epidural analgesia, oxycodone–paracetamol, and meloxicam. The primary outcome was pain with ﬂexion (POD14).
Results: Pregabalin did not reduce pain at rest, with ambulation, or with ﬂexion at 2 weeks (P=0.69, 0.23, and 0.90, respectively).
Pregabalin increased POD1 drowsiness (34.5, 37.9, 55.2, and 58.6% in the 0, 50, 100, and 150 mg arms, respectively; P=0.030), but
did not increase confusion (0, 3.5, 0, and 3.5%, respectively; P=0.75). Pregabalin had no effect on acute or chronic pain, opioid
consumption, or analgesic side-effects. Pregabalin reduced POD14 patient satisfaction [1–10 scale, median (ﬁrst quartile,
third quartile): 9 (8, 10), 8 (7, 10), 8 (5, 9), and 8 (6, 9.3), respectively; P=0.023). Protocol compliance was 63% by POD14 (50.0, 70.0,
76.7, and 56.7% compliance, respectively), with no effect of dose on compliance. Per-protocol analysis of compliant patients
showed no effect of pregabalin on pain scores.
Conclusions: Pregabalin had no beneﬁcial effects, but increased sedation and decreased patient satisfaction. This study does
not support routine perioperative pregabalin for total knee arthroplasty patients.
Clinical trial registration.: ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/show/study/NCT01333956.
Key words: analgesia; anticonvulsants; arthroplasty; knee; pain management; perioperative care; replacement

Perioperative pregabalin may reduce postoperative pain and opioid use,1 although this is controversial. Among total knee arthroplasty (TKA) patients, pregabalin 300 mg daily reduced acute
pain, chronic pain, and opioid intake.2 Pregabalin did not reduce

analgesic use after cosmetic3 or ankle surgery.4 A meta-analysis5
found that pregabalin reduced postoperative pain and reduced
analgesic drug intake, but only at doses ≥300 mg daily. Limitations of this meta-analysis include the limited dose–response
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Editor’s key points
• Pain in the recovery phase after knee arthroplasty can be
problematic and affect function.
• Evidence for pregabalin reducing pain and opioid use after
surgery is inconsistent.
• This study explored the effect of different pregabalin doses
on pain 14 days after surgery.
• Pregabalin did not improve analgesia, increased immediate
side-effects, and decreased patient satisfaction.
• Further work is needed to elucidate the role of pregabalin in
multimodal perioperative analgesia.

information that is available for pregabalin in the acute pain setting and the possibility that publication bias may have exaggerated the beneﬁt.6
Epidural analgesia combined with femoral nerve block and
oral analgesia initially provides good analgesia for TKA.7 However, pain after TKA can be severe and persistent. One report
found that ∼45% of patients had signiﬁcant postoperative pain
(visual analog scale >40) at 1 month, with a gradual decline to
∼12% of patients at 1 year.8 Another study reported control pain
scores 1 week after discharge [approximately postoperative day
(POD) 10] of 3.7 (interquartile range 2.9–4.7).9 Our own observational pilot study (conducted by J.T.Y.) found a mean (sd) Numeric
Rating Scale (NRS) pain score with activity of 4.8 (2.3) and at rest
2.4 (1.9) at 2 weeks after TKA in 40 patients (J.T.Y., unpublished
data). This corresponds to moderate to severe pain. This is clinically important because of the correlation between postoperative
pain and development of chronic pain.10 Buvanendran and colleagues2 administered pregabalin for 2 weeks (followed by a
rapid taper). In order to investigate the effects of pregabalin on
subacute pain after TKA, it seemed logical to assess pain at the
end of a 2 week period of pregabalin administration.
Side-effects of pain management may impair participation in
physical therapy and diminish patient satisfaction. At least 25%
of patients on POD1 after TKA have an Opioid-Related Symptom
Distress Scale (ORSDS) score >1 for nausea, drowsiness, itchiness,
and fatigue.11 Pregabalin could possibly reduce side-effects by reducing opioid use, or alternatively, could increase side-effects by
causing sedation or confusion. Doses of 300 mg day−1 increased
sedation and confusion on POD1.2
This prospective, randomized study compared placebo with
three doses of pregabalin [50, 100, and 150 mg twice daily (BID)],
in the hope that a lower pregabalin dose would improve analgesia
without increasing side-effects. The study tested the hypothesis
that pregabalin reduces pain after TKA and determined doserelated side-effects. Subacute pain (at 14 days) was studied
because of the perception that pain at 14 days was more of a
major clinical problem than chronic pain.

Methods
After providing informed written consent, 120 patients with osteoarthritis who were to undergo primary TKA with a participating
surgeon were enrolled (from May 2011 to March 2013). This study
was approved by the Hospital for Special Surgery Institutional Review Board and registered with clinicaltrials.gov (NCT01333956).
Eligible patients were 18- to 80-yr-old English speakers judged
able to follow the protocol, planned to have regional anaesthesia
and to be discharged home or to a participating rehabilitation
centre. Exclusion criteria included planned general anaesthesia,

allergy, or intolerance to one of the study medications, ASA physical status of IV, hepatic failure, renal failure (estimated creatinine
clearance <30 ml min−1), difﬁcult-to-manage diabetes mellitus (including insulin dependence), chronic gabapentin or pregabalin use
(regular use for longer than 3 months), chronic opioid use (regular
use for longer than 3 months), and major prior ipsilateral open
knee surgery.
Patients received preoperative oral meloxicam (Lupin Pharmaceuticals- Goa, India) (7.5 or 15 mg; lower dose used for age
≥75 yr) and dexamethasone (6 mg). An ultrasound-guided femoral nerve block was performed [0.25% bupivacaine (HospiraLake Forest, IL, USA), 30 ml, with adrenaline (Amphastar- So El
Monte, CA, USA), 5 μg ml−1], followed by a combined spinal and
epidural [10, 12.5, or 15 mg 0.5% plain bupivacaine, Lake Forest,
IL, USA]. Sedation consisted of midazolam (Hospira- Lake Forest,
IL, USA) and propofol (Hospira- Lake Forest, IL, USA) only. Postoperative patient-controlled epidural analgesia [bupivacaine
(Lake Forest, IL, USA) 0.06% plus hydromorphone (Akorn Pharmaceuticals- Lake Forest, IL, USA) 10 μg ml−1] was begun at 4 ml h−1; 4
ml bolus dose; 10 min lock-out; 20 ml h−1 maximum. The basal
rate became 2 ml h−1 at 07.00 h on POD1, and 0 ml h−1 at
17.00 h on POD1. The epidural was discontinued at noon on
POD2. Patients received postoperative daily meloxicam and oxycodone–paracetamol (Mallinckrodt- Hazelwood, MO, USA) (5 mg
oxycodone – 325 mg paracetamol every 4 hr as needed).
Patients were randomized to receive capsules containing 0, 50,
100, or 150 mg pregabalin (four groups of 30 patients per group).
Two capsules were given ∼30 min before transfer to the operating
room. Patients received one capsule twice a day until POD14 (total
daily dose of 0, 100, 200, or 300 mg pregabalin), then one capsule at
bedtime on POD15 and POD16. The computer-generated randomization table was prepared by a research assistant not otherwise
involved in the study. The hospital pharmacy prepared indistinguishable capsules. No other study personnel were aware of
group assignment. Patients were discharged with prescriptions
for meloxicam and oxycodone–paracetamol (Hazelwood, MO,
USA) (5 mg–325 mg), unless intolerance had occurred. Open-label
use of pregabalin or gabapentin was not allowed.
Preoperative data collection included the following patient
characteristics: age, sex, race, BMI, ASA status, and pain scores
at rest and with movement. Subsequent data collected included
the following: POD1 pain rating (NRS) at time of assessment
and with activity, confusion assessment method (CAM),12 opioid
usage, ORSDS, and other side-effects; POD3 NRS pain scores,
opioid usage, and ORSDS; and POD14 NRS pain scores, opioid
usage, ORSDS, compliance with administration of study drug,
blinding assessment, and satisfaction with pain management.
Drowsiness was assessed as a component of the ORSDS, which
was administered on POD1, 3, and 14. Satisfaction was assessed
by asking, ‘On a scale of 1 to 10, with 1 being ‘very dissatisﬁed’
and 10 being ‘very satisﬁed,’ how satisﬁed or dissatisﬁed are
you with the overall performance of the pain medication that
you received?’
At 3 months after surgery, opioid usage and neuropathic pain
were assessed. Neuropathic pain was evaluated as a binary
outcome [using a cut-off of 12 on the Leeds Assessment of
Neuropathic Symptoms and Signs (LANSS)] and by comparison
of LANSS scores as a continuum. The LANSS was administered
at 3 months only.
Patients can meet criteria for delirium by CAM by having acute
onset of inattention and either disorganized thinking or altered
level of consciousness. Patients without acute onset can also
meet criteria for delirium if inattention, disorganized thinking,
and altered level of consciousness are all present, with at least
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one factor judged to be ﬂuctuating.13 The CAM has been widely
applied12 and has been speciﬁcally used to evaluate elderly TKA
patients receiving epidural analgesia and femoral nerve block.14
The ORSDS is a four-point scale that evaluates 12 symptoms
(nausea, vomiting, constipation, difﬁculty passing urine, difﬁculty concentrating, drowsiness or difﬁculty staying awake, feeling lightheaded or dizzy, feeling confused, feelings of general
fatigue or weakness, itchiness, dry mouth, and headache) via
three symptom distress dimensions (frequency, severity, and
bothersomeness).15 It is validated for use after orthopaedic surgery, speciﬁcally including TKA patients receiving epidural analgesia and femoral nerve block.11
The LANSS has seven yes/no questions about ﬁve symptoms
and two signs associated with neuropathic pain; a self-administered LANSS was validated to identify neuropathic pain.16 The
LANSS was used as the primary outcome (at 3 and 6 months) to
evaluate pregabalin administration among TKA patients who received epidural analgesia.2
Study data were collected and managed using REDCap electronic
data capture tools hosted at the Hospital for Special Surgery.17
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Statistical analysis
An observational pilot study conducted by J.T.Y. at the Hospital
for Special Surgery from May 19, 2010 to May 18, 2011 in anticipation of powering a randomized interventional trial found a mean
() NRS pain score with activity of 4.8 (2.3) and at rest 2.4 (1.9) at 2
weeks after TKA in 40 patients (J.T.Y., unpublished data). We expected mean NRS pain scores with ﬂexion on POD14 (the primary
outcome) of 4.8, 4.0, 3.0, and 2.0 in the 0, 50, 100, and 150 mg pregabalin groups, respectively, with a within-group  of 2.5 points.
We calculated that 30 patients per arm (120 patients in total)
would provide 99% power with two-sided α of 0.05 to detect a linear
dose–response relationship between pregabalin dose and NRS
pain with ﬂexion using . We chose a sample size large enough to achieve high power for the primary outcome to allow for
precise estimation of postoperative sedation and confusion rates.
There were no stopping guidelines or interim analyses.
The primary efﬁcacy analysis used all available data, with each
patient analysed in the group to which they were originally assigned. Continuous outcome variables were compared between

Assessed for eligibility
(n=468)
Excluded
(n=348)
• Did not meet inclusion criteria
(n=145)
• Declined to participate
(n=109)
• Research staff unavailable for follow-up
(n=59)
• Not appropriate per MD
(n=35)
(g.e. early anticoagulation, cognitive impairment,
complicated case)

Randomized (n=120)

PLACEBO

PREGABALIN 50 mg

PREGABALIN 100 mg

PREGABALIN 150 mg

Allocated to intervention
(n=30)
• Received initial dose (n=30)

Allocated to intervention
(n=30)
• Received initial dose (n=30)

Allocated to intervention
(n=30)
• Received initial dose (n=30)

Allocated to intervention
(n=30)
• Received initial dose (n=30)

• Withdrew from study (n=2)

• Unsuccessful epidural (n=1)

• Lost to follow-up
POD14

Primary outcome analysed (n=28)

(n=1)

• Lost to follow-up
POD14

•

Withdrew form study (n=1)

(n=2)

Primary outcome analysed (n=26)

• Unsuccessful epidural (n=1)

•

Primary outcome analysed (n=29)

Lost to follow-up (n=1)
POD14

Primary outcome analysed (n=28)

Fig 1 Consolidated Standards of Reporting Trials diagram of patient ﬂow through the study. POD, postoperative day.

Table 1 Patient characteristics. BID, twice daily
Characteristic

Pregabalin
(0 mg; n=30)

Pregabalin (50 mg
BID; n=30)

Pregabalin (100 mg
BID; n=30)

Pregabalin (150 mg
BID; n=30)

Age [yr; mean (range)]
Sex (male/female; %)
BMI [kg m−2; mean ()]
Race
Caucasian
Other
ASA (I/II/III)

66 (34–79)
53%/47%
32 (5)

67 (54–77)
40%/60%
32 (6)

65 (53–79)
57%/43%
32 (6)

68 (44–80)
23%/77%
30 (7)

27
3
0/26/4

23
7
1/20/9

28
2
2/23/5

27
3
1/22/7
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Table 2 Pain scores. BID, twice daily; CI, conﬁdence interval; GEE, generalized estimating equations; POD, postoperative day
Time of
assessment

Pain with ﬂexion
Pain with ambulation
Pain at rest
GEE: pain with ﬂexion

Analysis type

POD14
POD14
POD14
POD1, 3, and 14,
and 3 months
POD1, 3, and 14,
and 3 months
POD1, 3, and 14,
and 3 months

Intent to treat
Intent to treat
Intent to treat
Intent to treat

Pain with ﬂexion

POD14

Pain with ambulation

POD14

Pain at rest

POD14

GEE: pain with ﬂexion

POD1, 3, and 14,
and 3 months
POD1, 3, and 14,
and 3 months
POD1, 3, and 14,
and 3 months

Per protocol (≥70%
compliant)
Per protocol (≥70%
compliant)
Per protocol (≥70%
compliant)
Per protocol (≥70%
compliant)
Per protocol (≥70%
compliant)
Per protocol (≥70%
compliant)

GEE: pain with
ambulation
GEE: pain at rest

GEE: pain with
ambulation
GEE: pain at rest

Pain with ﬂexion

POD14

Pain with ambulation

POD14

Pain at rest

POD14

GEE: pain with ﬂexion

POD1, 3, and 14,
and 3 months
POD1, 3, and 14,
and 3 months
POD1, 3, and 14,
and 3 months

GEE: pain with
ambulation
GEE: pain at rest

Pregabalin
(0 mg)

Pregabalin
(50 mg BID)

Pregabalin
(100 mg BID)

Pregabalin
(150 mg BID)

Omnibus

Linear trend

(n=28)

(n=26)

(n=29)

(n=28)

η2 (95% CI)

P-value

η2 (95% CI)

P-value

4.0 (2.3)
3.6 (2.0)
2.9 (2.3)
–

4.8 (2.1)
3.8 (1.6)
2.9 (2.0)
–

4.5 (2.4)
3.5 (1.8)
2.8 (1.8)
–

4.0 (2.1)
3.1 (1.9)
2.7 (2.1)
–

0.02 (0, 0.07)
0.02 (0, 0.07)
0 (0, 0)
–

0.55
0.57
0.98
0.72

0 (0–0.03)
0.01 (0–0.08)
0 (0–0.05)
–

0.90
0.23
0.69
0.47

Intent to treat

–

–

–

–

–

0.59

–

0.17

Intent to treat

–

–

–

–

–

0.91

–

0.99

Per protocol (100%
compliant)
Per protocol (100%
compliant)
Per protocol (100%
compliant)
Per protocol (100%
compliant)
Per protocol (100%
compliant)
Per protocol (100%
compliant)

(n=15)
3.9 (2.2)

(n=23)
4.7 (2.1)

(n=23)
4.9 (2.3)

(n=17)
3.2 (1.7)

0.10 (0, 0.21)

0.05

0.01 (0, 0.09)

0.40

3.3 (2.2)

3.6 (1.7)

3.7 (1.9)

2.4 (1.6)

0.07 (0, 0.18)

0.13

0.02 (0, 0.12)

0.18

2.8 (2.4)

3.0 (2.0)

2.8 (1.6)

2.4 (2.0)

0.01 (0, 0.06)

0.81

0.01 (0, 0.08)

0.49

–

–

–

–

–

0.59

–

0.30

–

–

–

–

–

0.35

–

0.07

–

–

–

–

–

0.97

–

0.82

(n=15)
3.9 (2.2)

(n=21)
4.8 (2.2)

(n=21)
4.9 (2.5)

(n=17)
3.2 (1.7)

0.10 (0, 0.21)

0.07

0.01 (0, 0.10)

0.38

3.3 (2.2)

3.6 (1.7)

3.6 (1.9)

2.4 (1.6)

0.07 (0, 0.17)

0.19

0.03 (0, 0.13)

0.18

2.8 (2.4)

3.0 (1.9)

2.7 (1.7)

2.4 (2.0)

0.01 (0, 0.07)

0.79

0.01 (0, 0.09)

0.46

–

–

–

–

–

0.57

–

0.32

–

–

–

–

–

0.28

–

0.05

–

–

–

–

–

0.99

–

0.78

Pregabalin and pain after knee arthroplasty

treatment arms via omnibus and linear-trend s. Effect sizes
corresponding with s were quantiﬁed as η2 values along
with 95% conﬁdence intervals (CIs). Ordinal variables were compared between groups with Kruskal–Wallis and Jonckheere–Terpstra tests, and binary variables were analysed using χ2 or Fisher’s
exact tests and Cochran–Armitage trend tests. Continuous data
measured at multiple time points were analysed with the generalized estimating equations method (GEE)18 19 using an autoregressive [AR(1)] correlation structure and adjusting for patient
characteristics and baseline value, where applicable. Bang blinding indices were calculated along with 95% CIs to assess the success of blinding.20
As a result of the unexpectedly low compliance rate by POD14,
we performed two per-protocol analyses of the primary outcome
(NRS pain with ﬂexion scores on POD14) as follows: (i) including
only patients who took at least 70% of capsules;21 and (ii) including only patients who took 100% of capsules. We performed post
hoc power calculations to re-examine our power, given the reduced sample sizes. Compliance rates by POD14 were tested for
linear and quadratic trends using logistic regression.
All statistical analyses were performed with SAS Version 9.3
(SAS Institute, Cary, NC, USA). All statistical tests were two
sided, with a value of P<0.05 considered statistically signiﬁcant.
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Moreover, pregabalin did not produce a dose-dependent decrease
in POD14 NRS pain score with ﬂexion (Table 2). Effect sizes
(η2 values) indicated that 2% of the variability in POD14 ﬂexion
NRS score can be explained by pregabalin dose.
The GEE analysis of NRS pain score with ﬂexion at all
postoperative time points (POD1, 3, and 14, and 3 months) did
not suggest an interaction between time point and pregabalin
dose (i.e. the relationship between pregabalin dose and NRS remained constant over time). The GEE analysis found no evidence
of a difference in mean NRS pain scores with ﬂexion between
treatment groups, after taking into account the postoperative
longitudinal measurements and adjusting for age, sex, BMI, and
baseline score (Table 2 and Fig. 2).
Pregabalin did not produce an overall difference among
groups or a dose-dependent decrease in NRS pain scores with
ambulation or at rest on POD14 (Table 2). The GEE analysis also
showed no differences for pain scores with ambulation and at
rest over time (Table 2).
The overall incidence of neuropathic pain at 3 months was
low [3/93; 3.2% (95% CI 1.1–9.0)]. There was no evidence of a difference in LANSS between groups (Table 3).
There was no evidence of an association between pregabalin dose and total opioid use after taking into account
longitudinal measurements and adjusting for patient characteristics (omnibus P=0.59, linear trend P=0.33, Fig. 3; total
opioid use, POD0, 1, 2, 3, and 14, and 3 months). Total opioid
use represents daily opioid use on POD0, 1, 2, 3, and 14, and
3 months.

Results
One hundred and twenty patients were enrolled (Fig. 1 and
Table 1). Two patients had failed epidurals. The primary outcome
was analysed in 111 patients.

Side-effects and other secondary outcomes
Pain outcomes and opioid use

The ORSDS evaluated side-effects on POD1, 3, and 14 (Table 3).
The only dose-dependent effect was an increase in drowsiness
on POD1.

Pregabalin did not produce an overall difference among groups
for POD14 NRS pain score with ﬂexion (the primary outcome).

10
9

NRS pain score with flexion

8
7
6
5
4
3
2
1
0
Preop

POD1

POD3
Time point

Pregabalin dose (mg)

0

POD14
50

100

3 Months

150

Fig 2 Pain scores with ﬂexion over time. Data are plotted as means with 95% conﬁdence intervals. POD, postoperative day; NRS, Numeric Rating Scale pain score.

0.01
0.10
0.62
0.62
23/30 (76.7%)
21/30 (70.0%)
15/29 (51.7%)
15/29 (51.7%)

23/30 (76.7%)
21/30 (70.0%)

17/29 (58.6%)
17/29 (58.6%)

0.09
0.38

–
–
–
–
–
–
0.03
0.32
0.86
0.75
0.02
0.84
0.16
0.49
0.69
0.99
0.07
0.17

–
–
0.94
0.97
0.30
0.84

0 (0, 6)
0.4 (0.2, 0.6)
0.3 (0.1, 0.5)
11/29 (37.9%)
6/26 (23.1%)
12/29 (41.4%)
1/28 (3.5%)
8 (7, 10)
4 (3, 4)
0 (0, 3)
0.4 (0.2, 0.7)
0.3 (0.1, 0.5)
10/29 (34.5%)
8/28 (28.6%)
10/29 (34.5%)
0/29 (0%)
9 (8, 10)
3 (3, 4)

Neuropathic pain [LANSS; median (Q1, Q3)]
Side-effect composite score, POD1 [ORSDS; median (Q1, Q3)]
Side-effect composite score, POD14 [ORSDS; median (Q1, Q3)]
Drowsiness, POD1 [ORSDS; n/total (%)]
Drowsiness, POD14 [ORSDS; n/total (%)]
Nausea, POD1 [ORSDS; n/total (%)]
Confusion, POD1 [CAM; n/total (%)]
Satisfaction, POD14 [median (Q1, Q3)]
Length of stay [days; median (Q1, Q3)]
Compliance
POD14≥70% compliant [n/total (%)]
POD14 100% compliant [n/total (%)]

0 (0, 0)
0.5 (0.2, 0.7)
0.3 (0.1, 0.5)
16/29 (55.2%)
12/29 (41.4%)
13/29 (44.8%)
0/29 (0%)
8 (5, 9)
3 (3, 4)

0 (0, 3)
0.4 (0.2, 0.8)
0.3 (0, 0.4)
17/29 (58.6%)
10/28 (35.7%)
9/29 (31.0%)
1/28 (3.5%)
8 (6, 9.3)
4 (3, 4)

P-value
linear trend
Pregabalin
(50 mg BID)
Pregabalin (0 mg)
Parameter

Pregabalin
(100 mg BID)

Pregabalin
(150 mg BID)

Omnibus

Quadratic
trend

| YaDeau et al.

Table 3 Confusion, drowsiness, nausea, length of stay, satisfaction, LANSS, and compliance. BID, twice daily; CAM, confusion assessment method; LANSS, Leeds Assessment of Neuropathic
Symptoms and Signs; ORSDS, Opioid-Related Symptom Distress Scale; POD, postoperative day; Q, quartile
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Confusion, as assessed by CAM on POD1, was rare, and there
was no evidence of a difference between groups (Table 3).
There was a dose-dependent decrease in satisfaction with
higher doses of pregabalin. There was no evidence of a difference
in hospital length of stay among groups (Table 3).
Although most patients (73%) were unwilling to guess treatment assignment, there was a statistically signiﬁcant excess of
correct guesses of treatment assignment by patients taking
pregabalin. The Bang blinding index20 was 0.10 ( pregabalin;
95% CI 0.01–0.19, P=0.041) and −0.07 ( placebo; 95% CI −0.23 to
0.09, P=0.76). The blinding index can range from 1 (complete unblinding) to −1 (opposite guessing); blinding index values near 0
indicate random guessing and support successful blinding.

Protocol compliance and per-protocol analysis
Protocol compliance can be categorized as ‘perfect compliance’,
‘partial compliance’, and ‘non-compliance.’22 Partial compliance
can be deﬁned as taking at least 70% of intended drug doses.21
Compliance rates were reasonable by POD3 (94% of patients
were at least 70% compliant, and 91% of patients were 100%
compliant).
Eighteen patients discontinued pregabalin in the hospital for
the following reasons: placebo group, one discontinuation ( patient unwilling to continue); 50 mg group, ﬁve discontinuations [one for confusion, one for difﬁculty concentrating and
unusual dreams ( patient requested discontinuation), and
three unwilling to continue]; 100 mg group, four discontinuations (one for cardiac arrest, one for sedation and hallucinations, and two unwilling to continue); and 150 mg group, eight
discontinuations [six for sedation or confusion, one for atrial ﬁbrillation ( patient requested discontinuation), and one unwilling
to continue].
By POD14, 66% of patients took at least 70% of study pills and
63% of patients took 100% of study pills (Table 3). Exploratory perprotocol analyses of NRS pain with ﬂexion scores using either (i)
patients who took at least 70% of capsules or (ii) patients who
took 100% of capsules found no difference in NRS pain scores
with ﬂexion between treatment groups (Table 2). These results
are similar to those of the primary efﬁcacy analysis. The sample
sizes available for the per-protocol analyses provide at least 80%
power to ﬁnd a linear trend or an overall difference between treatment groups (at the a priori estimates of mean and  of NRS pain
score with ﬂexion and α=0.05).

Discussion
This dose–response study was conducted with the hope of ﬁnding a pregabalin dose that would reduce pain without causing
major side-effects. The ﬁrst study hypothesis, that pregabalin reduces pain 2 weeks after TKA, was not supported by the trial. The
second study hypothesis, that pregabalin increases rates of drowsiness and confusion on POD1, was conﬁrmed for drowsiness, but
not for confusion. No beneﬁcial effects of pregabalin were noted;
no reduction occurred in acute pain, chronic pain, opioid consumption, or analgesic side-effects.
Pregabalin was associated with two adverse effects: increased
sedation and dose-dependent decreased patient satisfaction.
The pregabalin-associated reduction in satisfaction is probably
clinically relevant. Satisfaction scores [median (quartile 1, quartile 3)] decreased from 9 (8, 10) for placebo to 8 (6, 9.3) for 300
mg daily pregabalin. The minimal clinically signiﬁcant difference
on a 0–100 visual analog satisfaction scale was 7–11 mm,23 among
emergency department patients.
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Fig 3 Opioid use over time. Data are plotted as means with 95% conﬁdence intervals. POD, postoperative day.

This study reaches similar conclusions to the conclusions
found in a gabapentin study. Gabapentin (like pregabalin, a gabapentinoid) did not reduce morphine consumption or pain scores
and did not improve patient satisfaction after TKA.24 However,
Buvanendran and colleagues2 showed that administration of
300 mg pregabalin daily after TKA reduced pain scores but increased sedation and confusion on POD1.
The discordant result may be attributable to the many differences between this study and the study by Buvanendran and colleagues.2 Buvanendran and colleagues2 reported that NRS pain
scores at discharge with passive range of motion were 6.0 (2.3)
for pregabalin and 7.0 (2.2) for control patients. The POD3 pain
scores with ﬂexion among study patients were lower, at 4.2 (2.9)
for pregabalin 150 mg BID and 3.7 (2.6) for placebo. The difference
in pain control may be related to different analgesic protocols.
Buvanendran and colleagues2 used epidural analgesia (bupivacaine plus fentanyl, Lake Forest, IL, USA), oral opioids, and
celecoxib; in the present study, we used a single-injection bupivacaine (Lake Forest, IL, USA) femoral nerve block, epidural analgesia (bupivacaine plus hydromorphone, Lake Forest, IL, USA),
oral opioids, dexamethasone, and meloxicam. The primary outcome of the study by Buvanendran and colleagues2 was neuropathic pain at 6 months, whereas in the present study we used
the primary outcome of pain (NRS) at 14 days. Buvanendran
and colleagues2 found that pregabalin reduced the incidence of
neuropathic pain at 3 months from 8.7 to 0%. In the present
study, the overall rate of neuropathic pain at 3 months was
lower (3.2%) and was not inﬂuenced by pregabalin.
Pain after TKA can be severe if not treated aggressively.25 High
levels of acute pain after TKA are associated with increased rates
of chronic postsurgical pain,10 suggesting that improved treatment of acute pain may reduce the incidence of chronic pain.
However, pressure to mobilize patients rapidly may preclude

the use of analgesic regimens that interfere with participation
in postoperative physical therapy. The results of the present
study suggest that addition of pregabalin to the described analgesic regimen will not improve patient outcomes, decreases satisfaction, and increases sedation. The increased sedation could
interfere with physical therapy.
Strengths of the present study include the design; this was a
prospective, blinded, randomized dose–response trial, with
pregabalin prescribed for more than 14 days. Numerous outcomes were assessed ( pain scores at multiple times in multiple
conditions, opioid intake, analgesic side-effects, and patient
satisfaction).
Weaknesses of the study include insufﬁcient power for some
secondary outcomes, incomplete patient compliance, and the
fact that this is a negative study for the primary outcome. Trials
that fail to support their primary outcomes have a longer time to
publication and are less likely to be published.26 A recent pregabalin meta-analysis was not deﬁnitive because publication bias
may have exaggerated the beneﬁts of pregabalin,6 supporting
publication of negative pregabalin trials to reduce bias. Power calculations are prominent in evaluation of negative studies. The
data used for the power calculation [NRS pain score of 4.8 (2.3)]
were comparable to the observed primary result [4.0 (2.3), 4.8
(2.1), 4.5 (2.4), and 4.0 (2.1)]. This suggests that the preliminary
data used for the power analysis were valid and appropriate. Besides referring to the power analysis, it can be useful to compare
study size among similar studies. This study had 120 patients;
the three studies that demonstrated reduction of chronic pain
by pregabalin6 had 40,27 70,28 or 2402 subjects. Thus, this study
does not have an unusually small size compared with its peers.
Compliance in clinical trials is often not reported.29 The patient adherence rate in the present study was 63% for 14 days. To
place this in context, withdrawal rates in studies of antiepileptic
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drugs for chronic pain are typically 30% or more for 12 weeks.30
In the present study, rates of discontinuation were not apparently inﬂuenced by group; rates were similar in patients receiving placebo (50% compliant) and the highest dose of pregabalin
(56.7% compliant). This suggests that non-compliance was not
attributable to side-effects of pregabalin. Protocol adherence
diminished after discharge. Many outpatients do not take
prescribed medication. For example, after an acute myocardial
infarction the adherence rates for cardiovascular drugs are
66–76%.31 This study suggests that, in the real world outside of
hospital-based clinical trials, if pregabalin is prescribed for
pain after TKA, many patients will not take it for the full
14 days. Per-protocol analysis indicated that among compliant
patients no analgesic beneﬁt was noted, which suggests that
even if we could compel compliance, the pregabalin would
have no beneﬁt.
Future research on pregabalin for TKA patients could focus on
different analgesic regimens, on selection of patient groups likely
to beneﬁt, on use of pregabalin for patients reporting difﬁculties
with postoperative pain management, or on alternative scheduling of pregabalin.
Pregabalin might improve analgesia after TKA if given to
patients receiving a different, less comprehensive analgesic regimen. This study used an optimized analgesic regimen consisting
of neuraxial anaesthesia, epidural analgesia combined with peripheral nerve block,7 and multimodal oral analgesia. Total knee
arthroplasty patients managed with general anaesthesia and
opioids have high pain scores 25 that might be improved by
addition of pregabalin. Alternative anaesthetic and analgesic
regimens could include combinations of general anaesthesia,
i.v. opioids, continuous nerve block (femoral, adductor canal, or
sciatic), or local inﬁltration analgesia.
In summary, this study failed to ﬁnd beneﬁt from pregabalin
for analgesia after TKA. Pregabalin was associated with increased
drowsiness and reduced satisfaction with analgesia.
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